ProVee System for BPH
Proverum, Ltd. · Decision date Sep 24, 2026
What did the FDA approve?
The FDA record lists P250011/S006 for the ProVee System as an approved special (immediate track) supplement, dated 2026-09-24, with reason 'Process Change - Manufacturer/Sterilizer/Packager/Supplier.' The source statement describes 'the addition of a step to the ProVee System's final assembly process.' That is the full extent of the described change; the record does not name the added step, its equipment, controls or validation, so the technical scope beyond final assembly cannot be explained from these fields.
The S006 identifier places this action as a supplement to PMA P250011, not a new approval of the ProVee System as a whole. The device category for the parent filing is a permanent or semi-permanent prostatic or urethral stent, product code MER, sponsored by Proverum, Ltd. The stated purpose concerns a manufacturing process addition; the record itself is not independent proof of safety or clinical effectiveness and adds no indication or trial information.
FDA approval order statement
the addition of a step to the ProVee Systems final assembly process.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 24, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250011/S006
- Regulatory pathway
- PMA supplement
- Applicant
- Proverum, Ltd.
- Product code
- MER
- Decision code
- APPR
- Decision date
- Sep 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT.
- Applicant
- Proverum, Ltd.
- Product code
- MER
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250011 · Original PMA
ProVee System for BPH
P250011/S006 received
Application receipt date recorded by FDA.
P250011/S006 · FDA decision
Special (Immediate Track)
P250011/S005 · Related supplement
ProVee System for BPH
Timeline entries are records held by MedtechLedger for P250011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProVee System for BPHP250011 | Proverum, Ltd. | PMA approval | Dec 9, 2025 | FDA |
ProVee System for BPHP250011/S005 | Proverum, Ltd. | PMA supplement | Nov 3, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Proverum, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2nd Floor Astor Hall, 4-8 Eden Quay, Dublin, D01N5W8
Sources and methodology
- Original FDA record: P250011/S006
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
